AstraZeneca announces new insitro collaboration

Published on 10/17/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock has a dated company update. AstraZeneca announced a new insitro collaboration on October 15, 2026 for cardiometabolic therapies.

Dated company update

AstraZeneca announced its insitro collaboration on October 15, 2026.
The next Xetra session is scheduled for October 19, 2026.
AstraZeneca’s media center listed a separate HICKORY release dated October 11, 2026.

Schwarzweiß-Reportage: Reinraum-Mitarbeiter an Impfstoff-Abfülllinie — AstraZeneca plc (ISIN GB0009895292) fertigt Impfstoffe und Arzneimittel in hochmodernen, streng kontrollierten Reinraum-Produktionsanlagen, Illustration mit AI erstellt.

AstraZeneca announced a new strategic collaboration with insitro on October 15, 2026, focused on using advanced artificial intelligence systems to develop therapeutics for difficult-to-treat cardiometabolic diseases, according to AstraZeneca.

Weekend trading

The next price is shown from the start of trading by the continuously updated real-time quote of AstraZeneca stock.

Recent company releases

AstraZeneca’s media center also listed a separate release dated October 11, 2026, concerning efzimfotase alfa and results from the HICKORY Phase III trial. The release list is published by AstraZeneca.

Market context: Market report FTSE 100.